Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | HRAS | P01112 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.41 |
| ▸ | HK2 | P52789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7774709 | 0.95 | MAPK1 (0.50) | MAPK1LGALS3LGALS8HRASLGALS7; LGALS7B | |
| SCHEMBL31134199 | 0.90 | MAPK1 (0.58) | MAPK1LGALS3LGALS8HRASPOLB | |
| SCHEMBL8822997 | 0.90 | MAPK1 (0.58) | MAPK1LGALS3LGALS8HRASPOLB | |
| SCHEMBL1149280 | 0.87 | HRAS (0.47) | MAPK1LGALS3LGALS8HRASPOLB | |
| SCHEMBL11170170 | 0.85 | MAPK1 (0.65) | MAPK1LGALS3HRASPOLBTACR2 | |
| SCHEMBL15516519 | 0.84 | TP53 (0.55) | TACR2TP53MDM2 | |
| SCHEMBL12128062 | 0.84 | TACR2 (0.45) | LGALS3LGALS8HRASLGALS7; LGALS7BLGALS1 | |
| SCHEMBL12127996 | 0.84 | TACR2 (0.45) | LGALS3LGALS8HRASLGALS7; LGALS7BLGALS1 | |
| SCHEMBL9472134 | 0.84 | MAPK1 (0.54) | MAPK1LGALS3LGALS8HRASTACR2 | |
| SCHEMBL25913957 | 0.83 | TP53 (0.47) | MAPK1LGALS3LGALS7; LGALS7BLGALS1LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455659-B2 | Method for manufacturing neuraminic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20100035947-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035947-A1 | METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES | NEFM, NCDN, NTRK1 | MAPK1 2940/4885LGALS3 3440/4885LGALS8 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.